Global X Autonomous & Electric Vehicles vs Hinge Health Inc. Class A Common Stock — how do they compare? Global X Autonomous & Electric Vehicles trades at $30.99 (market cap $357.19M), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 23.7× Global X Autonomous & Electric Vehicles's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Global X Autonomous & Electric Vehicles nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Autonomous & Electric Vehicles for 41 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| DRIV | HNGE | |
|---|---|---|
Market Cap | $357.19M | $8.48B |
Volume | 24,175 | 879,799 |
Sector | Sector/Thematic | Health |
52-Week High | $42.53 | $105.14 |
52-Week Low | $27.60 | $31.17 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | — | $8.10B |
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $32.06, down slightly by 0.06% today. Technical indicators show mixed signals with a bullish overall signal but bearish moving averages. The stock faces resistance at $34 with support at $33. Recent news highlights automotive sector dynamics including hybrid vehicle growth and China's EV ambitions, which could impact DRIV's market positioning.
The outlook for DRIV is cautiously optimistic given sector tailwinds from hybrid and EV adoption, though key financial ratios remain unavailable for fundamental assessment. Risks include oil price volatility and competitive pressures. Analyst sentiment appears balanced with equal buy/sell technical signals, suggesting investors should monitor upcoming earnings for clearer direction.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →